Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

semaglutide

- PMLiVE

Risk calculator to prevent heart attacks and strokes in type 2 diabetes patients

About one-third of adults living with diabetes die from a heart or circulatory disease

- PMLiVE

Novo Nordisk announces $2.3bn investment to expand production site in France

The investment will increase the manufacturing capacity for Novo's GLP-1 products

- PMLiVE

Eli Lilly’s tirzepatide injection approved by MHRA and FDA for weight loss in adults

The drug has been authorised for use alongside a reduced-calorie diet and physical activity

- PMLiVE

Novartis shares positive phase 3 results for atrasentan in rare kidney disease

The company gained access to the candidate after it acquired Chinook Therapeutics

- PMLiVE

Novo Nordisk to buy KBP’s hypertension drug ocedurenone for up to $1.3bn

An estimated 1.28 billion adults aged 30 to 79 years worldwide have hypertension

- PMLiVE

AstraZeneca’s Forxiga shows promise in paediatric type 2 diabetes trial

The prevalence of type 2 diabetes in children and adolescents is increasing globally

- PMLiVE

Novo Nordisk and Valo Health agree deal worth up to $3.3bn to develop cardiovascular treatments

The companies will work together to develop new cardiovascular treatments

- PMLiVE

Eli Lilly’s Mounjaro receives NICE recommendation to treat type 2 diabetes

Around 180,000 patients with type 2 diabetes could benefit from the new treatment option

- PMLiVE

Novo Nordisk enters new research alliance for diabetes and cardiometabolic diseases

The collaboration will focus on advancing three programmes across the next three years

- PMLiVE

Boehringer and Lilly’s Jardiance granted MHRA approval to treat chronic kidney disease

Approximately 7.2 million people in the UK are affected by the long-term kidney condition

- PMLiVE

Novo Nordisk acquires Embark Biotech in deal worth over €470m

Novo gains access to Embark's lead asset targeting obesity and other cardiometabolic diseases

- PMLiVE

Vironix and Oxford University partner to advance chronic kidney disease monitoring

The partners will aim to develop learning models that predict the progression of CKD

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links